Market capitalization | $1.24b |
Enterprise Value | $971.36m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 8.97 |
P/S ratio (TTM) P/S ratio | 11.45 |
P/B ratio (TTM) P/B ratio | 5.90 |
Revenue growth (TTM) Revenue growth | -4.42% |
Revenue (TTM) Revenue | $108.30m |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
11 Analysts have issued a Wave Life Sciences Ltd. forecast:
11 Analysts have issued a Wave Life Sciences Ltd. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 108 108 |
4%
4%
|
|
Gross Profit | 100 100 |
4%
4%
|
|
EBITDA | -102 -102 |
73%
73%
|
EBIT (Operating Income) EBIT | -110 -110 |
62%
62%
|
Net Profit | -97 -97 |
68%
68%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
Head office | Singapore |
CEO | Paul Bolno |
Employees | 288 |
Founded | 2012 |
Website | www.wavelifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.